Patient enrolment and treatment delivery
From December 2019 to August 2022, the study was active at 9 investigational sites. A total of 187 patients provided informed consent to initiate the process of personalized neoTCR discovery. After successfully obtaining the appropriate quality of baseline biopsy samples and PBMCs for DNA sequencing and RNA-seq, 88 patients (47%) participated in the neoTCR discovery process. Of these participants, 46 (52%) met the requirements for successful product selection for clinical manufacture (Fig. 